Drug development begins with uncomfortable odds. For most early-stage assets, the likelihood of approval (LOA) and probability of technical and regulatory success (PTRS) are low. Depending on therapeutic area, modality, stage of development, and the benchmark being used, only a...
William Bainbridge
A Target Product Profile (TPP) serves as the primary strategic framework that aligns commercial and clinical workstreams. When properly defined, the TPP enables drug developers to manage the development equation of risk x cost x time = success, and it...